Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Ofatumumab
Monoclonal Antibody · Antineoplastic
Also known as ARZERRA
Monoclonal AntibodyAntineoplastic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Ofatumumab is a humanized IgG monoclonal antibody that binds to the CD20 molecule on B lymphocytes at distinct sites on the major and minor extracellular loops of CD20. This binding leads to B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). It lyses B-CLL cells in the presence of complement and mediates ADCC, leading to depletion of CD20+ B cells.
Indications
Chronic lymphocytic leukemia (CLL) after failure of fludarabine and alemtuzumabChronic lymphocytic leukemia (CLL) in patients who are refractory to fludarabine and alemtuzumabUntreated chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine, only if the patient is ineligible for fludarabine-based therapyRelapsing multiple sclerosisCLL after failure of fludarabine and alemtuzumab
Dosing
- Adult
- A complex dosing scheme is used, beginning with small (300 mg) doses on day 1, followed by higher doses (up to 2 g/week) for 7 weeks, followed by 2 g every 4 weeks for four additional doses. Slow rates of infusion are recommended for the initial dose and for the first 2 hours of subsequent infusions.
Contraindications
- Active hepatitis B infection
- patients with active hepatitis B infection
Side effects
Common
ImmunosuppressionOpportunistic infectionHypersensitivity reactions during antibody infusionMyelosuppression
Serious
- Prolonged myelosuppression
- Reactivation of viral infections
- Progressive multifocal leukoencephalopathy (PML)
- Hepatitis B progression/reactivation
- immunosuppression
- opportunistic infection
- myelosuppression
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Ofatumumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team